Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials

Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib. The study aimed to identify pre-treatment patient characteristics predictive of developing severe rash with vemurafenib therapy.